Harvard Bioscience (HBIO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $8.31, +1.96% vs the prior close of $8.15.
- Volume 16.60K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
HBIO rises 2.0% to $8.31. Closed at $8.31, +1.96% vs the prior close of $8.15. Day range $7.95–$8.40, opened at $8.21.
HBIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — HBIO rises 2.0% to $8.31
- Closed at $8.31, +1.96% vs the prior close of $8.15. Day range $7.95–$8.40, opened at $8.21.
- Volume was 16.60K shares, 0.8x its 50-day average of 19.72K.
- Price is +7.5% vs its 50-day average ($7.73) and +31.3% vs its 200-day average ($6.33).
- 52-week range $3.80–$9.40; today's close sits at 81% of that range, 11.6% below the 52-week high.
Oct 14, 2026 — HBIO dips 1.5% to $8.15
- Closed at $8.15, -1.45% vs the prior close of $8.27. Day range $7.90–$8.37, opened at $8.12.
- Volume was 11.60K shares, 0.6x its 50-day average of 19.63K — lighter than usual.
- Price is +6.0% vs its 50-day average ($7.69) and +29.0% vs its 200-day average ($6.32).
- 52-week range $3.80–$9.40; today's close sits at 78% of that range, 13.3% below the 52-week high.
Oct 13, 2026 — HBIO rises 0.4% to $8.27
- Closed at $8.27, +0.36% vs the prior close of $8.24. Day range $8.19–$8.49, opened at $8.27.
- Volume was 6.50K shares, 0.3x its 50-day average of 19.77K — lighter than usual.
- Price is +8.0% vs its 50-day average ($7.66) and +31.0% vs its 200-day average ($6.31).
- 52-week range $3.80–$9.40; today's close sits at 80% of that range, 12.0% below the 52-week high.
Oct 12, 2026 — HBIO ends flat (+0.0%) to $8.24
- Closed at $8.24, +0.00% vs the prior close of $8.24. Day range $8.23–$8.53, opened at $8.42.
- Volume was 8.90K shares, 0.4x its 50-day average of 20.03K — lighter than usual.
- Price is +8.2% vs its 50-day average ($7.62) and +30.6% vs its 200-day average ($6.31).
- 52-week range $3.80–$9.40; today's close sits at 79% of that range, 12.3% below the 52-week high.
Oct 9, 2026 — HBIO rises 1.4% to $8.24
- Closed at $8.24, +1.35% vs the prior close of $8.13. Day range $8.10–$8.47, opened at $8.10.
- Volume was 12.40K shares, 0.6x its 50-day average of 19.92K.
- Price is +8.8% vs its 50-day average ($7.57) and +30.7% vs its 200-day average ($6.30).
- 52-week range $3.80–$9.40; today's close sits at 79% of that range, 12.3% below the 52-week high.
Oct 8, 2026 — HBIO slides 4.4% to $8.13
- Closed at $8.13, -4.35% vs the prior close of $8.50. Day range $7.98–$8.80, opened at $8.47.
- Volume was 18.00K shares, 0.9x its 50-day average of 19.66K.
- Price is +8.0% vs its 50-day average ($7.53) and +29.0% vs its 200-day average ($6.30).
- 52-week range $3.80–$9.40; today's close sits at 77% of that range, 13.5% below the 52-week high.
Oct 7, 2026 — HBIO dips 0.7% to $8.50
- Closed at $8.50, -0.70% vs the prior close of $8.56. Day range $8.43–$8.60, opened at $8.43.
- Volume was 8.30K shares, 0.4x its 50-day average of 19.68K — lighter than usual.
- Price is +13.5% vs its 50-day average ($7.49) and +35.0% vs its 200-day average ($6.30).
- 52-week range $3.80–$9.40; today's close sits at 84% of that range, 9.6% below the 52-week high.
Oct 6, 2026 — HBIO rises 0.7% to $8.56, a 52-week high, 4 up days in a row
- Closed at $8.56, +0.71% vs the prior close of $8.50. Day range $8.51–$8.66, opened at $8.51.
- Volume was 10.30K shares, 0.5x its 50-day average of 19.63K — lighter than usual.
- Price is +15.1% vs its 50-day average ($7.44) and +36.0% vs its 200-day average ($6.29).
- 52-week range $3.80–$9.40; today's close sits at 85% of that range, 8.9% below the 52-week high.
- That makes 4 straight gains.
Oct 5, 2026 — HBIO rises 1.9% to $8.50, a 52-week high, 3 up days in a row
- Closed at $8.50, +1.92% vs the prior close of $8.34. Day range $8.40–$8.80, opened at $8.44.
- Volume was 23.00K shares, 1.2x its 50-day average of 19.29K.
- Price is +15.1% vs its 50-day average ($7.39) and +35.1% vs its 200-day average ($6.29).
- 52-week range $3.80–$9.40; today's close sits at 84% of that range, 9.6% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — HBIO rises 2.6% to $8.34, a 52-week high
- Closed at $8.34, +2.58% vs the prior close of $8.13. Day range $8.03–$8.42, opened at $8.08.
- Volume was 15.50K shares, 0.8x its 50-day average of 19.09K.
- Price is +13.7% vs its 50-day average ($7.34) and +32.7% vs its 200-day average ($6.28).
- 52-week range $3.80–$9.40; today's close sits at 81% of that range, 11.3% below the 52-week high.
HBIO latest news & SEC filings
Every SEC filing by or about HBIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 22, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $22.73M (prior year $20.45M) (+11.1% vs Jun 30, 2025)
- Net income: -$2.91M (prior year -$2.28M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.64 (prior year -$0.52) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade HBIO
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 12, 2026, Feb 10, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.22% (largest 4.4%).
- Liquidity: about 17.27K shares (≈$143.51K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.31 vs a range of $3.80–$9.40 (81% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Mar 16, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 5 open-market buys, 0 sales; latest: Stephen J Denelsky bought 10,000 shares on Mar 17, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 4.55M shares outstanding (Aug 4, 2026), -89.8% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Laboratory Analytical Instruments.
HBIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 8.21 | 8.40 | 7.95 | 8.31 | 16.60K |
| Oct 14, 2026 | 8.12 | 8.37 | 7.90 | 8.15 | 11.60K |
| Oct 13, 2026 | 8.27 | 8.49 | 8.19 | 8.27 | 6.50K |
| Oct 12, 2026 | 8.42 | 8.53 | 8.23 | 8.24 | 8.90K |
| Oct 9, 2026 | 8.10 | 8.47 | 8.10 | 8.24 | 12.40K |
| Oct 8, 2026 | 8.47 | 8.80 | 7.98 | 8.13 | 18.00K |
| Oct 7, 2026 | 8.43 | 8.60 | 8.43 | 8.50 | 8.30K |
| Oct 6, 2026 | 8.51 | 8.66 | 8.51 | 8.56 | 10.30K |
| Oct 5, 2026 | 8.44 | 8.80 | 8.40 | 8.50 | 23.00K |
| Oct 2, 2026 | 8.08 | 8.42 | 8.03 | 8.34 | 15.50K |
| Oct 1, 2026 | 7.90 | 8.13 | 7.85 | 8.13 | 45.70K |
| Sep 30, 2026 | 7.94 | 7.97 | 7.85 | 7.92 | 15.10K |
| Sep 29, 2026 | 8.00 | 8.07 | 7.88 | 7.96 | 26.60K |
| Sep 28, 2026 | 7.96 | 8.07 | 7.92 | 7.98 | 32.30K |
| Sep 25, 2026 | 8.02 | 8.05 | 7.92 | 7.96 | 5.00K |
| Sep 24, 2026 | 8.02 | 8.13 | 7.96 | 8.02 | 15.60K |
| Sep 23, 2026 | 7.90 | 8.09 | 7.90 | 8.05 | 23.20K |
| Sep 22, 2026 | 8.02 | 8.09 | 7.91 | 7.92 | 11.60K |
| Sep 21, 2026 | 8.03 | 8.10 | 7.90 | 8.00 | 20.00K |
| Sep 18, 2026 | 8.00 | 8.19 | 7.95 | 7.95 | 19.20K |
About Harvard Bioscience
Harvard Bioscience (HBIO) is listed on the Nasdaq and classified by the SEC under “Laboratory Analytical Instruments”. Its business address is in HOLLISTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1123494.
HBIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Seth Benjamin Benson | Director | Jun 11, 2026 |
| Stephen J Denelsky | Director | Jun 11, 2026 |
| John D Duke | Chief Executive Officer | Mar 23, 2026 |
| Katherine A. Eade | Director | Jun 12, 2026 |
| Robert E. Gagnon | Director | Jun 11, 2026 |
| William Snider | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John D Duke | Chief Executive Officer | Mar 23, 2026 |
| Mark T Frost | Chief Financial Officer | Apr 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 17, 2026 | Stephen J Denelsky | Buy | 10,000 | $4.87 |
| Mar 17, 2026 | William Snider | Buy | 8,475 | $4.85 |
| Mar 16, 2026 | William Snider | Buy | 12,525 | $4.99 |
| Mar 16, 2026 | John D Duke | Buy | 5,000 | $5.01 |
| Mar 16, 2026 | Mark T Frost | Buy | 5,000 | $5.00 |
HBIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $86.55M | $-56.70M | -1.28 | $6.73M |
| Dec 31, 2024 | $94.14M | $-12.40M | -0.28 | $1.44M |
| Dec 31, 2023 | $112.25M | $-3.42M | -0.08 | $14.03M |
| Dec 31, 2022 | $113.33M | $-9.52M | -0.23 | $1.15M |
| Dec 31, 2021 | $118.90M | $-288.00K | — | $1.26M |
Latest balance sheet: total assets $76.29M, total liabilities $68.87M, cash $6.50M (as of Jun 30, 2026).
HBIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $6.13 |
| May 12, 2026 | 8-K Item 2.02 (results) | $5.41 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $4.90 |
| Feb 10, 2026 | 8-K Item 2.02 (results) | $6.00 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $5.50 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $4.80 |
| May 12, 2025 | 8-K Item 2.02 (results) | $3.50 |
| Mar 12, 2025 | 8-K Item 2.02 (results) | $6.90 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $23.90 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Laboratory Analytical Instruments
Illumina (ILMN)Waters (WAT)Mettler Toledo International Inc/ (MTD)Revvity (RVTY)Agilent Technologies (A)10x Genomics (TXG)Bruker (BRKR)Avantor (AVTR)Bio-Rad Laboratories (BIO)Alamar Biosciences (ALMR)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on HBIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.